Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vincent Deorchis

Neurology New Hyde Park, NY Medical Doctor

NPI 1396995916 CMS profile 153968

1991 Marcus Ave, Suite 110, New Hyde Park, NY 11042

Open in the dashboard

General payments

$54,550

993 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Deorchis of New Hyde Park, NY is reported in the CMS Open Payments database as having received $54,550 across 993 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,975 200
2024 General $25,618 212
2023 General $3,462 214
2022 General $2,692 156
2021 General $2,267 112
2020 General $324 21
2019 General $1,211 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Deorchis
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Vincent Deorchis were reported at $18,975. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Vincent Deorchis Neurology median Middle half National median
2019 $1,211 $474 $118–$2,177 $163
2020 $324 $367 $82–$2,309 $114
2021 $2,267 $438 $104–$2,547 $132
2022 $2,692 $442 $103–$2,388 $149
2023 $3,462 $464 $119–$2,312 $160
2024 $25,618 $468 $119–$2,323 $164
2025 $18,975 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $30,740 154 payments
  2. Ceribell, Inc. $8,795 7 payments
  3. Biogen, Inc. $1,276 101 payments
  4. Pfizer Inc. $1,002 66 payments
  5. Neurocrine Biosciences, Inc. $873 51 payments
  6. SK Life Science, Inc. $813 63 payments
  7. Amgen Inc. $783 39 payments
  8. EMD Serono, Inc. $729 37 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $656 23 payments
  10. Alexion Pharmaceuticals, Inc. $640 32 payments
  11. Other $8,244 420 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,525 13 payments
  2. Food and Beverage $17,870 963 payments
  3. Consulting Fee $8,795 7 payments
  4. Travel and Lodging $290 5 payments
  5. Education $69 5 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $16,090 75 payments
  2. UBRELVY $14,818 84 payments
  3. POCKET EEG DEVICE $8,795 7 payments
  4. Leqembi $812 37 payments
  5. TYSABRI $780 62 payments
  6. INGREZZA $723 40 payments
  7. NURTEC ODT Pain $570 41 payments
  8. NURTEC ODT Primary Care $558 22 payments
  9. AIMOVIG $490 27 payments
  10. ULTOMIRIS $485 23 payments
  11. Other $11,806 669 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,197

Median for Neurology: 833

Drug cost

$576,670

Median for Neurology: $202,670

Branded share of claims

24.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 65 $119,497
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 17 $119,266
Ubrelvy Ubrogepant Brand 55 $85,109
Droxidopa Generic 19 $66,666
Qulipta Atogepant Brand 28 $39,849
Ongentys Opicapone Brand 24 $34,458
Rivastigmine Generic 68 $16,155
Memantine Hcl Er Memantine Hcl Brand 53 $14,880
Ajovy Autoinjector Fremanezumab-Vfrm Brand 18 $13,571
Namzaric Memantine Hcl/Donepezil Hcl Brand 11 $12,764

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$297,248

Medicare's payments for the services billed

Medicare patients

1,198

Average age 78

Services billed

3,089

632 women, 566 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Ischemic heart disease 54%
Diabetes 36%
Atrial fibrillation 30%
Depression 27%
Chronic kidney disease 24%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$10,228 28 —
UBRELVY
$7,054 55 —
Leqembi
$330 — —
HYQVIA
$205 — —
RELYVRIO
$179 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

993 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record